文献速递核素与放射性配体治疗肿瘤 PET/CT

177Lu标记AKIR001靶向CD44v6治疗胰腺癌的临床前疗效与联合策略

[177Lu]Lu-AKIR001 for CD44v6-Positive Pancreatic Cancer: Preclinical Efficacy and Combination Strategies.
PubMed 文献 · J Nucl Med · 2026-09-02

该临床前研究评估了靶向CD44v6的放射药物[177Lu]Lu-AKIR001单用及联合化疗治疗胰腺导管腺癌(PDAC)的疗效。4个PDAC细胞系中3个表达CD44v6,荷瘤小鼠中肿瘤摄取超过100 %IA/g,肿瘤生长抑制呈活性依赖性,12 MBq单药组40%达完全缓解,4 MBq联合紫杉醇组14%达完全缓解。结论认为该药物具有活性依赖性治疗潜力,联合紫杉醇可能协同获益,但需进一步研究和优化。

要点

  • 4个PDAC细胞系中3个表达CD44v6,为靶向治疗提供依据。
  • 荷瘤小鼠肿瘤摄取超过100 %IA/g,肿瘤生长抑制呈活性依赖性。
  • 12 MBq单药组40%完全缓解,4 MBq联合紫杉醇组14%完全缓解。

核心结论

  • [177Lu]Lu-AKIR001在PDAC荷瘤小鼠中显示活性依赖性治疗潜力,联合紫杉醇可能协同获益,但需进一步研究和优化。

研究设计与样本

  • 临床前研究:评估PDAC细胞系CD44v6表达、放射性配体结合及化疗敏感性,荷瘤小鼠接受单药、化疗或联合治疗,通过体重监测及血液学与器官分析评估毒性。

主要发现

  • 4个PDAC细胞系中3个表达CD44v6。
  • 荷瘤小鼠肿瘤摄取超过100 %IA/g。
  • 肿瘤生长抑制呈活性依赖性,12 MBq [177Lu]Lu-AKIR001组40%达完全缓解。
  • 4 MBq [177Lu]Lu-AKIR001联合紫杉醇组14%达完全缓解。

局限性

  • 结论基于小鼠荷瘤模型,需进一步研究和优化后方可转化临床。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Pancreatic ductal adenocarcinoma (PDAC) is highly aggressive, with a 5-y survival rate of less than 5% for patients with advanced disease. CD44v6 is frequently overexpressed in the malignancy, representing a promising therapeutic target. Here, we evaluated the efficacy of [177Lu]Lu-AKIR001, a CD44v6-targeting radiopharmaceutical, alone and combined with chemotherapy for the treatment of PDAC. Methods: CD44v6 expression, radioligand binding, and chemotherapy sensitivity were assessed in PDAC cell lines. Mice bearing PDAC xenografts received [177Lu]Lu-AKIR001, chemotherapy, or a combination of the two modalities. Toxicity was determined by body weight monitoring and hematologic and organ analyses. Results: Three of the 4 cell lines expressed CD44v6. In vivo, tumor uptake exceeded 100 %IA/g. Tumor growth inhibition was activity-dependent, with complete remissions detected after the administration of 12 MBq of [177Lu]Lu-AKIR001 (40%) and 4 MBq of [177Lu]Lu-AKIR001 combined with paclitaxel (14%). Conclusion: [177Lu]Lu-AKIR001 demonstrated activity-dependent therapeutic potential in mice bearing PDAC xenografts. Combination therapy with paclitaxel indicated potential synergistic benefit, but further investigation and optimization are warranted.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Gustafsson A, Svedberg H, Rinne SS, et al. [177Lu]Lu-AKIR001 for CD44v6-Positive Pancreatic Cancer: Preclinical Efficacy and Combination Strategies. J Nucl Med. 2026. PMID: 42020146. doi:10.2967/jnumed.125.271705

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。